You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The partners aim to enable the early prediction of clinical efficacy of Alligator's pipeline candidates by analyzing potential systemic biomarkers.
The company plans to develop tests for prostate cancer risk assessment, prostate cancer screening, and breast cancer screening.
The Medicare contractor proposed coverage for several cancer assays, but would not cover molecular respiratory virus assays or a test for inflammatory bowel disease.
New data from Peregrine Pharmaceuticals, along with other recent research, suggests that surface proteins can be used to isolate cancer-specific exosomes to detect the presence of a tumor.
Researchers showed it could differentiate pancreatic cancer cases from controls with high sensitivity, and believe it could work similarly for other cancers or in infectious disease.
The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.
New data suggest that measuring AR-V7 expression only in the nuclei of circulating tumor cells might better predict therapeutic benefit in prostate cancer patients.
Bio-Techne will provide a bioanalytical assay for the group to assess and validate as a bioanalytical method for clinical trial recruitment.
The company developed the instrument using in-licensed technology coupled with its own chemistry and other technology for exosomal protein analysis.
The team will use the new research grant to further develop the Stockholm3 prostate cancer test and to design follow-on diagnostics to help treat patients with the disease.
Retraction Watch writes that a cancer researcher has had an eighth paper retracted.
Computational biologist James Taylor has died, according to Johns Hopkins University.
The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.
In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.